The global peptide synthesis market is experiencing dramatic expansion as pharmaceutical companies and research institutions accelerate investment in peptide-based therapeutics. Industry analysts project the market will nearly triple from $861 million in 2024 to $2.3 billion by 2033, representing an 11.4% compound annual growth rate. Major Manufacturing Capacity Expansions Signal Industry Confidence Recent capital investments […]

On September 29th, 2025, the US Food and Drug Administration (FDA) issued two letters reversing its previous position on beta-nicotinamide mononucleotide (NMN), confirming that the ingredient is lawful for use in dietary supplements. This decision overturns the agency's earlier interpretation that excluded NMN under the drug preclusion clause of the Food, Drug and Cosmetic Act […]

Nicotinamide adenine dinucleotide (NAD) has become a prominent topic in wellness circles, with social media influencers and celebrities discussing its potential benefits. The compound, naturally found in all human cells, plays a role in energy production within the mitochondria. As NAD levels decline with age, some theorize that supplementation could restore these levels and support […]

Chill Brands, a prominent vape and CBD retailer, has reported a significant decline in UK sales as retailers reduce their stock of disposable vapes in anticipation of the upcoming ban scheduled for June 2025. The company has announced it is shifting its focus toward developing reusable vaping products in response to the changing regulatory landscape. […]

The Drug Enforcement Administration (DEA) recently postponed its decision on reclassifying marijuana under federal law, with a hearing set for December 2, 2024. This delay means that any final decision on marijuana rescheduling won’t be made until after the November presidential election, potentially delaying until 2025. The rescheduling, proposed by the Biden administration, follows an […]